Search

Displaying results 2101 - 2110 of 7452 in total
  1. Drug

    Nalidixic acid

    go.drugbank.com/drugs/DB00779
    ApprovedWithdrawn

    Nalidixic acid is a synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA gyrase.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  2. Drug

    Influenza A virus A/Kansas/14/2017 X-327 (H3N2) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB15516
    Approved

    In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. … Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3.

    Mixtures: FLUARIX TETRA SUSPENSION FOR INJECTION
  3. Drug

    Fluvoxamine

    go.drugbank.com/drugs/DB00176
    ApprovedInvestigational

    Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine...

    Categories: Antidepressive Agents Indicated for Depression
  4. Drug

    Clotiazepam

    go.drugbank.com/drugs/DB01559
    ApprovedIllicit

    Clotiazepam is a thienodiazepine, not approved for sale in the U.S. or Canada, but has been approved in the U.K. It is a schedule IV drug in Canada.

  5. Drug

    Evinacumab

    go.drugbank.com/drugs/DB15354
    ApprovedInvestigational

    [L31838] In September and December 2023, evinacumab was also approved by Health Canada and EMA, respectively, for the same indication.[L49956,L49966] … hypolipidemia and subsequent reductions in cardiovascular risk, whereas increases in function appear to be associated with cardiovascular risk, and it was these observations that provided a rationale for

  6. Drug

    Palbociclib

    go.drugbank.com/drugs/DB09073
    ApprovedInvestigational

    [L5867] It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male

  7. Drug

    Milnacipran

    go.drugbank.com/drugs/DB04896
    ApprovedInvestigational

    Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment … yet approved the agent for such treatment, citing lack of robust evidence of efficacy, insufficient demonstration of maintenance of effect, and other concerns [F3928, F3934].

  8. Drug

    Varenicline

    go.drugbank.com/drugs/DB01273
    ApprovedInvestigational

    become aggressive or black out. … Food and Drug Administration warned that Varenicline, in the form of Pfizer Inc's quit-smoking drug, Chantix, has been associated with seizures and that some patients who drink while taking the drug may

  9. Drug

    Bafilomycin A1

    go.drugbank.com/drugs/DB06733
    Experimental

    These compounds all appear in the same fermentation and have similar biological activity. Bafilomycins are specific inhibitors of vacuolar-type H+-ATPase. (V-ATPase).

  10. Drug

    Seladelpar

    go.drugbank.com/drugs/DB12390
    ApprovedInvestigational

    [L51149] On August 14, 2024, seladelpar was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis,[L51154] which is a condition associated with aberrant bile acid metabolism